Skip to main content

Table 5 Cellular biomarkers and oxidative damage and their association to SIL and cervical cancer development

From: TOP2A/MCM2, p16INK4a, and cyclin E1 expression in liquid-based cytology: a biomarkers panel for progression risk of cervical premalignant lesions

  NSILa LSIL HSIL CC
OR OR CI p OR CI p OR CI p
TOP2A/MCM2 1.0 22.5 9.3–54.1 <0.001 900.8 240.3–3376 <0.001 2484 507–∞ <0.001
p16INK4a 1.0 10.1 4.6–22.2 <0.001 138.1 42.6–447.8 <0.001 320.6 75.0–∞ <0.001
Cyclin E 1.0 10.0 4.6–21.3 <0.001 109.9 36.3–333.2 <0.001 533.0 123.3–∞ <0.001
Ki-67 1.0 6.7 3.4–13.2 <0.001 121.4 40.9–360.3 <0.001 522.8 121.5–∞ <0.001
Telomerase 1.0 13.7 6.1–30.7 <0.001 85.7 26.2–280.5 <0.001 165.9 39.2–∞ <0.001
RI-5 1.0 58 18.5–186.1 <0.001 4012 755–21,323 <0.001 8290 1309–∞ <0.001
RI-4 1.0 29.5 11.3–76.8 <0.001 1482 340.8–6461 <0.001 3878 691–∞ <0.001
RI-3 1.0 40.2 14.2–114.4 <0.001 2924 592–14,429 <0.001 5913 998–∞ <0.001
RI-2 1.0 24.5 9.9–60.8 <0.001 1290 306.8–5429 <0.001 3020 526–∞ <0.001
ROS 1.0 1.8 1.4–2.3 <0.001 1.2 0.8–1.8 0.30 0.5 0.3–0.8 0.004
8-OHdG 1.0 4.4 2.7–7.2 <0.001 3.6 1.9–6.6 <0.001 5.3 2.8–10.0 <0.001
  1. NSIL Non-squamous intraepithelial lesions, LSIL Low-grade squamous intraepithelial lesions, HSIL High-grade squamous intraepithelial lesions, CC Cervical cancer, OR Odds ratio, CI Confidence interval, RI Risk index; RI-5 analysis with TOP2A/MCM2, p16INK4a, cyclin E, Ki-67, and telomerase; RI-4 analysis with TOP2A/MCM2, p16INK4a, cyclin E, and Ki-67; RI-3 analysis with TOP2A/MCM2, p16INK4a, and cyclin E; RI-2 analysis with TOP2A/MCM2 and p16INK4a OR adjusted by age and HPV infection by oncogenic risk (HPV negative, HR, PHR, LHR, and UHR) areference category